Cardio Diagnostics Holdings, Inc. announced that it has entered into subscription agreements with 7 accredited investors to issue a total of 561,793 units at a price of $1.78 per Unit for gross proceeds of $999,991.54 on February 2, 2024. Each Unit consisting of one share of the company?s common stock, $0.00001 par value and one six year common stock purchase warrant, having an exercise price of $1.78 per share. The Private Placement resulted in the issuance to investors of 561,793 shares of Common Stock and 561,793 Warrants in an unregistered offering of securities.

The company intends to register for resale the shares of Common Stock and the Common Stock issuable upon exercise of the Warrants within 180 days from the closing date. The issuance of the Common Stock, the Warrants and the Placement Agent Warrants, as well as the Common Stock issuable upon exercise of the Warrants and the Placement Agent Warrants, is exempt from the registration requirements of the Securities Act of 1933, as amended in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated thereunder. Altitude Capital Group, LLC was paid a cash commission equal to 10% of the gross proceeds received by the company, plus 20% warrant coverage, providing it with the right to purchase 112,353 shares of Common Stock at $1.78 per share through February 2, 2030.

The company has received ($1,000,0000) in funding pursuant to exemption provided under Regulation D. The transaction included participation from 7 investors.